- Home
- PTGX
PTGX
Protagonist Therapeutics Inc.
as 04-18-2025 1:42pm EST
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | NEWARK |
| Market Cap: | N/A | IPO Year: | 2016 |
| Target Price: | $66.50 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 4.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $24.22 - $60.60 | Next Earning Date: | 05-06-2025 |
| Revenue: | $434,433,000 | Revenue Growth: | 624.05% |
| Revenue Growth (this year): | -76.8% | Revenue Growth (next year): | 7.13% |
Stock Insider Trading Activity of Protagonist Therapeutics Inc. (PTGX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Waddill William D. | PTGX | Director | Mar 17 '25 | Sell | $54.25 | 4,000 | $217,000.00 | 13,130 | |
| MOLINA ARTURO MD | PTGX | Chief Medical Officer | Mar 13 '25 | Sell | $55.74 | 30,514 | $1,700,850.36 | 83,892 | |
| Ali Asif | PTGX | Chief Financial Officer | Mar 12 '25 | Sell | $58.73 | 24,903 | $1,462,553.19 | 62,821 | |
| PATEL DINESH V PH D | PTGX | President and CEO | Feb 19 '25 | Sell | $38.18 | 5,359 | $204,606.62 | 540,260 |
Latest Protagonist Therapeutics Inc. News
PTGX Breaking Stock News: Dive into PTGX Ticker-Specific Updates for Smart Investing
ACCESS Newswire
3 days ago
Protagonist Therapeutics Reports Granting of Inducement Award
Argus Research
3 days ago
PTGX: Raising target price to $49.00
ACCESS Newswire
9 days ago
Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill
Argus Research
10 days ago
PTGX: Lowering target price to $44.00
Argus Research
17 days ago
PTGX: Lowering target price to $49.00
Argus Research
24 days ago
PTGX: Lowering target price to $54.00
Zacks
25 days ago
Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?
Insider Monkey
a month ago
Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025?
Compare PTGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PTGX Protagonist Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.